There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Accolade (ACCD – Research Report), PROCEPT BioRobotics (PRCT – Research Report) and Day One Biopharmaceuticals (DAWN – Research Report) with bullish sentiments.
Accolade (ACCD)
Stifel Nicolaus analyst David Grossman maintained a Buy rating on Accolade today and set a price target of $13.00. The company’s shares closed last Thursday at $9.19.
According to TipRanks.com, Grossman is a 4-star analyst with an average return of
Currently, the analyst consensus on Accolade is a Moderate Buy with an average price target of $13.38, representing a 45.9% upside. In a report issued on April 18, Leerink Partners also maintained a Buy rating on the stock with a $16.00 price target.
See today’s best-performing stocks on TipRanks >>
PROCEPT BioRobotics (PRCT)
Piper Sandler analyst Matthew O’Brien maintained a Buy rating on PROCEPT BioRobotics today and set a price target of $58.00. The company’s shares closed last Thursday at $52.28, close to its 52-week high of $54.79.
According to TipRanks.com, O’Brien is a 4-star analyst with an average return of
Currently, the analyst consensus on PROCEPT BioRobotics is a Strong Buy with an average price target of $57.50, which is a 10.8% upside from current levels. In a report issued on April 15, Truist Financial also maintained a Buy rating on the stock with a $63.00 price target.
Day One Biopharmaceuticals (DAWN)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Day One Biopharmaceuticals today and set a price target of $40.00. The company’s shares closed last Thursday at $13.21.
According to TipRanks.com, Catanzaro is a 4-star analyst with an average return of
Day One Biopharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $36.56, implying a 147.0% upside from current levels. In a report issued on April 16, Capital One Financial also maintained a Buy rating on the stock with a $40.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACCD:
